Treatment of dna damage related disorders

Abstract

The present invention provides methods and compositions for the treatment of DNA damage related disorders. One embodiment of the invention is a prophylactic method for the prevention of cancer using a chloroquine compound. Another embodiment is a method for the inhibition of side effects associated with chemotherapeutic and radiotherapeutic agents using chloroquine compounds.

1 . A method of prophylactic treatment for a DNA damage related disorder comprising administering to an animal subject in need thereof an effective amount of a chloroquine compound, with the proviso that the chloroquine compound does not prevent a localized skin carcinoma alone.  
     
     
         2 . The method of  claim 1  wherein the chloroquine compound prevents a localized skin carcinoma and at least one cancer that is not a localized skin carcinoma.  
     
     
         3 . The method of  claim 1  wherein the DNA damage related disorder is aging.  
     
     
         4 . The method of  claim 1  wherein the DNA damage related disorder is cancer.  
     
     
         5 . The method of  claim 1  wherein the DNA damage related disorder is caused by radiation, toxins, carcinogens, natural processes or exposure to agents which cause oxidative DNA damage.  
     
     
         6 . A method of inhibiting side-effects of radiation therapy comprising administering to an animal subject in need thereof an effective amount of a chloroquine compound.  
     
     
         7 . A method of inhibiting development of secondary cancers comprising administering to an animal subject in need thereof an effective amount of a chloroquine compound.  
     
     
         8 . A method of inhibiting side-effects of chemotherapy comprising administering to an animal subject in need thereof an effective amount of a chloroquine compound.  
     
     
         9 . A prophylactic method of prevention of X-ray related DNA damage comprising administering to an athlete in need thereof an effective amount of a chloroquine compound.  
     
     
         10 . The method of claims  1 ,  6 ,  7 ,  8 , or  9  wherein the chloroquine compound is selected from the group consisting of chloroquine, chloroquine phosphate, hydroxychloroquine, chloroquine diphosphate, chloroquine sulphate, hydroxychloroquine sulphate, or enantiomers, derivatives, analogs, metabolites, pharmaceutically acceptable salts, and mixtures thereof.  
     
     
         11 . The method of  claim 10  wherein the compound is chloroquine, chloroquine phosphate or chloroquine diphosphate.  
     
     
         12 . The method of claims  1 ,  6 ,  7 ,  8 , or  9  wherein chloroquine compound has a systemic effect.  
     
     
         13 . The method of claims  1 ,  6 ,  7 ,  8 , or  9  wherein the amount of the compound administered is at least about 0.1 mg/kg/day.  
     
     
         14 . The method of claims  1 ,  6 ,  7 ,  8 , or  9  wherein the amount of the compound administered is up to about 10 mg/kg/day.  
     
     
         15 . The method of claims  1 ,  6 ,  7 ,  8 , or  9  wherein the amount of the compound administered is more than about 0.1 mg/kg/day.  
     
     
         16  The method of claims  1 ,  6 ,  7 ,  8 , or  9  wherein the amount of the compound administered is more than about 1.0 mg/kg/day.  
     
     
         17 . The method of claims  1 ,  6 ,  7 ,  8 , or  9  wherein the amount of the compound administered is less than about 50 mg/kg/day.  
     
     
         18 . The method of claims  1 ,  6 ,  7 ,  8 , or  9  wherein the amount of the compound administered is less than about 10 mg/kg/day.  
     
     
         19 . The method of claims  1 ,  6 ,  7 ,  8 , or  9  wherein the chloroquine compound is administered more than once a week.  
     
     
         20 . The method claims  1 ,  6 ,  7 ,  8 , or  9  wherein the chloroquine compound is administered daily.  
     
     
         21 . The method of claims  1 ,  6 ,  7 ,  8 , or  9  wherein the chloroquine compound is formulated in a sustained release formulation.